Oral vaccination against poliomyelitis and vaccine-associated paralytic poliomyelitis in Germany: Is there a need for a new vaccination strategy?;SCHLUCKIMPFUNG GEGEN POLIOMYELITIS UND IMPFASSOZIIERTE PARALYTISCHE POLIOMYELITIS IN DEUTSCHLAND. BRAUCHEN WIR EINE NEUE IMPFSTRATEGIE?

Wiener Medizinische Wochenschrift

Volumn 147, Issue 19-20, 1997, Pages 456-461

  Fescharek, R ^a   Arras Reiter, C ^a   Arens, E R ^a   Quast, U ^b   Maass, G ^c  

^a Chiron Behring GmbH & Co   (Germany)

^b QCB Quast Consulting Biologica   (Germany)

^c Deutschen Vereinigung zur Bckampfung   (Germany)

Author keywords

Epidemiology; Vaccination strategy; Vaccine associated paralytic poliomyelitis

Indexed keywords

INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; MALE; PARALYSIS; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; SEROTYPING;

EID: 0030688939     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Andrus JA, et al: Risk of vaccine-associated paralytic poliomyelitis in Latin America. 1989-1991. Bull WHO 1995;73:33-40.
2. Certification of Poliomyelitis Eradication in the Americas. 1994. Münch Med Wschr 1994;43:720-723.
3. Expanded Programme on Immunization: Statement on poliomyelitis eradication. Week Epidemiol Rec 1995;49:345-347.
4. Frankel DH: US group urges polio immunisation change. Lancet 1995;346:1151.
5. Huber EG, Stück B: Position Paper of the Symposium "Strategies towards poliomyelitis-eradication". Bad Fuschl, Austria, October 1995.
6. Joce R, et al: Paralytic Poliomyelitis in England and Wales, 1985-91. Br Med J 1992;305:79-82.
7. Maass G, Quast U: Acute spinal paralysis after the administration of oral poliomyelitis vaccine in the Federal Republic of Germany (1963-1984). J Bio Standard 1987;15:185-191.
8. Mandell GL, Douglos RG jr, Bennett JE: Paralysis is more common in boys. In: Principles and practice of infectious diseases. New York. Churchill Livingstone, 1990, p 1363.
9. Marwick C: Will US polio-immunization rely on IPV or OPV? JAMA 1995;274:12-13.
10. Nkowane BM, et al: Vaccine Associated Paralytic Poliomyelitis. United States: 1973 Through 1984. JAMA 1987;257:1335-1340.
11. Plotkin SA, Mortimer EA: Vaccines. 2nd ed. Philadelphia, Saunders, 1984, p 156.
12. Pöhn HP: Poliomyelitis-Schutzimpfungen in der Bundesrepublik Deutschland einschließlich Berlin (West), 1968-1976. Bundesgesundheitsblatt 1978;21:129-134.
13. Prevots DR, et al: Completeness of Reporting for Paralytic Poliomyelitis. United States, 1980 Through 1991. Implications for Estimating the Risk of Vaccine-Associated Disease. Arch Pediatr Adolesc Med 1994;148:479-485.
14. Robert Koch-lnstitut (eds): Poliomyelitis in Deutschland. Vorkommen - Diagnostik - Impfempfehlungen. Epidemiol Bull 1996;1:3-5.
15. Shaw FE, Graham DJ, Guess HA, et al: Postmarketing surveillance for neurologic and adverse events reported after hepatitis B vaccination. Am J Epidemiol 1988;127:337-352.
16. Stratton K, Howe C, Johnston RB (eds): Adverse events associated with childhood vaccines. Evidence bearing on causality. Washington DC, National Academy Press, 1994.
17. Strebel PM, Sutter RW, Cochi SL, et al: Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Inf Dis 1992;14:568-579.
18. WHO consultative group: The relation between acute persisting spinal paralysis and poliomyelitis vaccine - results of a ten-year enquiry. Bull WHO 1982;60:231-242.